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Introduction
Thrombin generation within the systemic circulation can drive complex changes in blood associated with coagulopathy. During trauma, for example, major changes in blood biochemistry occur as a result of hemorrhagic shock, release of tissue factor (TF) into the vasculature, endothelial release of tPA, endothelial glycocalyx shedding and systemic inflammatory events [1] [2] [3] . Following trauma, thrombin and plasmin are generated in the systemic circulation, as indicated by elevated plasma levels of thrombin-antithrombin, fibrin degradation products and activated protein C [4] [5] [6] [7] .
Soluble fibrin monomer or soluble fibrin in various states of multimerization can circulate for several hours [8] and reach levels of 100 nM in trauma-induced coagulopathy (TIC) patients [9] , 40 nM in Day-0 trauma patients (estimated from fibrinopeptide A levels) [10] , 90 nM in neck fracture patients [11] , 54 nM in sepsis patients [12] , 42 nM in coronary artery disease patients [13] , 30-300 nM in extracorporeal membrane oxygenation (ECMO) patients [14] , and up to 67 nM in postoperative abdominal aortic aneurysm (AAA) patients [15] , all relative to a healthy human baseline of~7.5 nM soluble fibrin monomer [13] . Also, soluble fibrin exceeds 600 nM (50X baseline) in the rat model of Noble-Collip drum trauma [16] .
Platelets obtained from trauma patients can display a hypofunctional phenotype, potentially contributing to TIC [17, 18] . Platelet dysfunction after trauma has been detected by aggregometry [7, 19] , by thromboelastography [17] , and by microfluidic assay of platelet deposition on collagen [20] . Interestingly, trauma patients often display no significant differences in baseline platelet count or platelet P-selectin levels compared with healthy individuals [7] .
Platelet GPVI is an immunoglobulin superfamily receptor [21] present at about 4000 copies/platelet [22] , corresponding to about 1 nM concentration in platelet-rich plasma (PRP). Known GPVI-activating ligands include collagen, collagen-related peptide (CRP) and convulxin [23, 24] , as well as fibronectin [23] , vitronectin [24] and laminins [25] . Within a forming clot and on fibrin-coated surfaces, insoluble fibrin has recently been described as a ligand and agonist of platelet GPVI signaling [21, 26] . Platelet GPVI binding to fibrin surfaces increases platelet procoagulant activity [21] , amplifies collagen-independent thrombin generation and platelet recruitment at the clot surface [26] , and contributes to thrombus growth and stabilization [21, 27] .
However, the function of soluble fibrin species on platelets in suspension is less well understood, because circulating platelets may eventually encounter a wound site presenting various adhesive matrix stimuli such as collagen, vitronectin and laminin. Fibrinogen can be activated to desA and desB soluble fibrin monomer, which will immediately bind fibrinogen (an assembly also considered, confusingly, as soluble fibrin monomer). Additionally, thrombin activity results in assemblies of submicron soluble fibrin multimers (< 50 monomer units), which are easily detectable by light scattering. In diluted apixabantreated PRP where added thrombin is consumed without further thrombin generation, these dilute, soluble multimeric fibrin species are stable in suspension and never reach a concentration to form long fibrin strands, laterally aggregated bundles or fibrin gels (insoluble fibrin). We use the term 'soluble fibrin' to refer to submicron desA/B fibrin multimeric assemblies that may also contain bound fibrinogen. The fibrin polymerization inhibitor Gly-Pro-Arg-Pro (GPRP) keeps soluble fibrin monomer from binding fibrinogen or assembling into longer multimer units.
We hypothesized that platelet hypofunction can result from exposure to low levels of thrombin and/or thrombin-generated plasma species such as soluble fibrin.
Because elevated soluble fibrin levels have been implicated in trauma and disseminated intravascular coagulation (DIC) [16, [28] [29] [30] , understanding GPVI signaling after soluble fibrin exposure has clinical implications. We developed approaches using apixaban-treated, diluted PRP that allows addition of low-dose thrombin (t 1/2~1 min via inhibition by antithrombin) to trigger limited fibrin monomer generation without formation of an insoluble fibrin gel for studies of platelet GPVI signaling in the presence of soluble fibrin species.
Material and methods

Platelet calcium assays
Apixaban and GM6001 (SelleckChem, Houston, TX, USA), Fluo-4 NW dye and probenecid (Invitrogen, Carlsbad, CA, USA), ADP, GPRP, PGE 1 , apyrase and Factor Xa (Sigma-Aldrich, St. Louis, MO, USA), convulxin (Cayman Chemical, Ann Arbor, MI, USA), thrombin and human fibrinogen (Haematologic Technologies Inc., Essex Junction, VT, USA), PAR-1/4 agonist peptides (Bachem, Torrance, CA, USA), U46619 (Tocris Bioscience, Bristol, UK), T101 (Zedira GmbH, Darmstadt, Germany), vorapaxar (Ryan Scientific, Mt. Pleasant, SC, USA), and GR144053 (R&D Systems, Minneapolis, MN, USA) were stored and used according to the manufacturers' instructions. Whole blood was drawn by venipuncture from healthy donors with University of Pennsylvania Institutional Review Board approval into a syringe containing apixaban (final concentration, 250 nM) to prevent factor Xa-driven generation of thrombin. Donors self-reported that they were free of any medications or alcohol use for 3 days prior to the blood draw. Female donors selfreported not using oral contraceptives.
Platelet calcium measurements were conducted in a 384-well plate assay as previously described [31] . Briefly, 2 mL PRP was obtained from whole blood (120 9 g centrifugation, 10 min) and incubated with a vial of Fluo-4 NW dye mixture reconstituted with 7.8 mL of sterile 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffered saline (HBS, pH 7.4) and 200 lL of 77 mg mL À1 probenecid for 30 min. In some experiments, GPRP and/or vorapaxar were added with the calcium dye to give final concentrations of 500 lM and/or 100 nM, respectively. Additionally, a 384-well plate containing platelet agonists was assembled, including thrombin, ADP, U46619 (a stable thromboxane analog), SFLLRN and AYPGKF (PAR-1 and PAR-4 receptor agonists), as well as convulxin (a potent and specific GPVI activator). Dyeloaded PRP was then dispensed into a 384-well plate. Both plates were loaded into a FlexStation 3 (Molecular Devices, Inc., Sunnyvale, CA, USA) fluorescence reader. Agonists were dispensed column-wise to PRP, where dynamic fluorescence intensity F(t) was read and normalized by the pre-dispense baseline (F o ). For all experiments, 10 lL of agonist was added to 30 lL of PRP in each well, followed by a subsequent addition of 10 lL of convulxin at a later specified time. In each well, the final concentration of PRP after agonist addition was 12% PRP by volume. The fluorescence was read for 20 s before first dispense, and readings were taken every 2.5 s (Ex: 485 nm; Em: 525 nm). In previous tests, there was no evidence for autocrine signaling in the dilute PRP conditions of the experiment [31] . In calcium experiments using washed platelets instead of PRP, 500 nM human fibrinogen was added. In this case, the platelet pellet from 2 mL PRP was resuspended in 1.1 mL of HBS to obtain a washed platelet suspension. For calcium assay using type 1 fibrillar collagen (Chronolog, Havertown, PA, USA), PRP was prepared as described; however, the small FlexStation automation pipettes resulted in variable delivery, thus requiring manual pipetting and assay using a FluoroSkan Ascent 384-well plate reader.
Microfluidic assays
Fluorescent human fibrinogen (Thermo Fisher Scientific, Alexa Fluor Ò 647 conjugate, Waltham, MA, USA) was reacted with thrombin (2.5 nM final concentration) for 5 min after a 15-min incubation with either 5 mM GPRP or HBS (to prevent or allow fibrin polymerization, respectively), after which D-Phenylalanyl-prolyl-arginyl Chloromethyl Ketone (PPACK; Haematologic Technologies Inc., Essex Junction, VT, USA) was added (100 lM final concentration) to inhibit thrombin. The mixture was then diluted 10-fold into whole blood that had been drawn into PPACK (100 lM) and apixaban (1 lM). Platelets were labeled using PE fluorescent anti-CD61 (BD Biosciences, San Jose, CA, USA). The eight-channel microfluidic device was fabricated out of polydimethylsiloxane (PDMS) (Ellsworth Adhesives, Germantown, WI, USA) as previously described [32] . The device was blocked with 0.5% bovine serum albumin (BSA; SigmaAldrich) for 30 min before sample perfusion (each channel: 60 lm high, 250 lm wide). Apixaban/PPACK-treated whole blood was perfused through the device using a syringe pump (Harvard Apparatus, Holliston, MA, USA) at a wall shear rate of 200 s À1 over a patterned 250-lm-long strip of 1 mg mL À1 fibrillar collagen type 1 (Chronolog).
The deposited platelet and fibrin fluorescence intensities were recorded every minute for 6 min.
Results
Thrombin, but not ADP or U46619, attenuated subsequent platelet GPVI signaling
Addition of thrombin (1-10 nM) to diluted apixaban-treated PRP caused a dose-dependent calcium mobilization (Fig. 1A) . Pretreatment with thrombin, however, resulted in a marked inhibition of calcium mobilization when 20 nM convulxin was added 480 s after thrombin (Fig. 1A) . In the absence of thrombin pretreatment, convulxin drives a massive and sustained calcium mobilization lasting over 700 s. Dasatinib, a Src family/Syk inhibitor, blocked convulxin-induced GPVI signaling with minimal effect on Ga q agonists of calcium mobilization (via thrombin, U46619 and ADP), thus confirming that convulxin is activating GPVI with concomitant calcium mobilization dependent on Syk signaling ( Figure S1 ). Even the lowest dose of thrombin (1 nM), which caused minimal calcium mobilization, had significant inhibitory effect on GPVI activation by convulxin. However, convulxin insensitivity was not observed when ADP or U46619 were added instead of thrombin (Fig. 1B, C) , even though both agonists caused dose-dependent calcium mobilization similar to that evoked by thrombin treatment.
When ADP was added instead of thrombin, a very low dose of ADP (10 nM) did not affect subsequent calcium response to convulxin compared with the control condition (Fig. 1B) . Low to medium doses of ADP (100 nM-1 lM) slightly increased subsequent calcium response to convulxin. A high dose of ADP (10 lM) resulted in a detectable reduction in subsequent final platelet calcium response to convulxin, but not nearly to the extent seen in the case of thrombin. When U46619 was used as the first stimulus, very low to medium doses of U46619 (10 nM-1 lM) did not affect subsequent calcium response to convulxin compared to the control condition (Fig. 1C) . Similarly, as seen in the case of ADP, a high dose of U46619 (10 lM) resulted in a detectable reduction in subsequent final platelet calcium response to convulxin, but not nearly to the extent caused by any dose of thrombin. In a related experiment, thrombin treatment of apixabantreated PRP caused a marked loss in platelet sensitivity to CRP ( Figure S2 ), although 25 lg mL À1 CRP was not as potent as 20 nM convulxin in activating platelet GPVI. Type I fibrillar collagen (20 lg mL
À1
) was tested as a platelet agonist instead of convulxin. In this unstirred reaction, the platelet calcium response to collagen alone was slower than that observed with convulxin alone. As seen with convulxin and CRP, pretreatment of the PRP with thrombin (2-10 nM) resulted in a complete insensitivity to subsequent exposure to fibrillar collagen ( Fig. 2A-C) .
Thrombin-induced GPVI-signaling defect was time dependent
Convulxin (20 nM) was added to PRP at varying times after thrombin addition (1-2 nM). When convulxin was added after low-dose thrombin (1 nM) incubation times of 150, 210 and 335 s, the calcium signal in response to convulxin was comparable to the control condition in which PRP was not first activated by thrombin (Fig. 3A) . However, when the incubation time with 1 nM thrombin increased to 480 s, subsequent calcium responses to convulxin decreased significantly. When a slightly higher dose of thrombin (2 nM) was first added to PRP, subsequent calcium responses to convulxin were not attenuated until incubation times increased to 210 s or higher (Fig. 3B) . The onset time of convulxin insensitivity depended on the thrombin dose (Fig. 3C) . In comparing peak calcium response to convulxin (no thrombin pretreatment) with that obtained with prior thrombin treatment, an incubation with 2 nM thrombin for 220 s or incubation with 1 nM thrombin for 500 s led to a marked 80% reduction in convulxin-triggered GPVI signaling. ), fully consistent with the previous findings using convulxin. Additionally, collagen and convulxin show significantly different kinetic profiles of GPVI signaling, which can be attributed to the molecular composition of each species. Collagen, a larger and more fibrillar molecule, activates GPVI in a slower but more sustained manner, whereas convulxin elicits a rapid and transient response.
Activating PAR-1 and PAR-4 does not result in attenuation of GPVI signaling
Thrombin signals through Ga q -linked PAR-1 and PAR-4 receptors in human platelets, but when PAR-1 and PAR-4 agonists (SFLLRN and AYPGKF) were added to PRP (instead of active thrombin), the subsequent platelet calcium response to convulxin was unaffected compared with the control condition (Fig. 4A ). In combination with the observations with ADP and U46619, this result indicated that thrombin activity played a unique role other than through Ga q -dependent signaling via PAR-1/ 4. When vorapaxar, a PAR-1 specific inhibitor was added, calcium signaling in response to 10 nM thrombin was fully blocked (Fig. 4B) . However, when thrombin was added to PRP incubated with vorapaxar, the lack of thrombin-induced calcium mobilization had no effect on the subsequent thrombin-dependent GPVI-signaling defect when convulxin was added (Fig. 4C) . In separate calcium mobilization experiments using PAR-1 and PAR-4 activating peptides, vorapaxar was found to be a PAR-1 selective inhibitor ( Figure S3 
The results shown in Figs 1-4 are fully consistent with thrombin acting on a plasma element to attenuate platelet sensitivity to GPVI agonists. This was confirmed in an assay comparing the effect of thrombin pretreatment of washed platelets versus PRP. Thrombin pretreatment of washed platelets caused substantial calcium mobilization, but had little effect on the GPVI response to convulxin ( Figure S4 ), confirming the role of thrombin in a plasma component. We next tested the ability of GPRP to block soluble fibrin multimerization and rescue GPVI function in the presence of active thrombin. When thrombin was first added to PRP incubated with GPRP, the subsequent calcium response to convulxin was completely normal when compared with the control condition where no thrombin was first added (Fig. 5A ). This demonstrated that soluble fibrin assembly was essential for the thrombin-induced ablation of platelet sensitivity to convulxin. GPRP rescued GPVI sensitivity to convulxin for thrombin pretreatment concentrations ranging from 2 to 20 nM ( Figure S5 ). Unlike thrombin, the P2Y 1 /P2Y 12 agonist ADP does not induce polymerization of fibrinogen into fibrin. Therefore, as expected, when the experiment in Fig. 5(A) was repeated with ADP instead of thrombin, GPRP had no effect on the subsequent calcium response to convulxin (Fig. 5B) . Notably, in the calcium responses to thrombin alone, the calcium signal displayed an upward trend, consistent with soluble fibrin acting as a weak GPVI activator [21] . However, in cases with GPRP present, the thrombin-induced calcium mobilization was transient and eventually returned to baseline (Fig. 5C ).
Because fibrin assembly was required for convulxin insensitivity, we tested if FXIIIa activity played a role in thrombin-induced GPVI attenuation. Interestingly, the FXIIIa inhibitor T101 had little effect on platelet response to thrombin, but caused a marked reduction in the thrombin-induced convulxin insensitivity (Fig. 6A,B) . Additionally, T101 alone had little effect on the convulxin response of platelets without thrombin pretreatment. T101 was unable to overcome the attenuation of GPVI at the highest thrombin concentration tested (20 nM).
As GPVI activators such as CRP (as well as thrombin) can cause GPVI dimerization [33, 34] and shedding by metalloproteases such as a-disintegrin-and-metalloproteinase 10 (ADAM-10), we tested the role of shedding in thrombin-induced GPVI-signaling deficiency. Treatment of PRP with the metalloprotease inhibitor GM6001 had little effect on the ability of thrombin to attenuate platelet response to convulxin (Fig. 6C) . GPRP maintained its ability to prevent thrombin-induced convulxin insensitivity in the presence of GM6001.
Use of the a IIb b 3 inhibitor, GR144053, inhibited fibrinogendependent platelet aggregation (via aggregometry) as expected; however, GR144053 did not alter the thrombin-mediated attenuation of convulxin-induced signaling ( Figure S6 ). This finding eliminates the potential role of fibrin(ogen)-driven integrin a IIb b 3 outside-in signaling in the observed deficiency in response to GPVI agonists. These results indicate that GPVI shedding and a IIb b 3 -mediated fibrin binding were not the cause of convulxin insensitivity in the presence of soluble fibrin, even when soluble fibrin served as a relatively weak agonist for platelet GPVI. When soluble fibrin is formed in the presence of vorapaxar (to prevent thrombin activation), there is little change in calcium signal (Fig. 4C) , indicating that the generation of soluble fibrin is not strongly activating in this system. However, in this experiment with vorapaxar present, a marked convulxin insensitivity was observed (an effect fully reversed by GPRP and indicative of soluble fibrin driving the GPVI-signaling deficiency).
Thrombin treatment of washed platelets in purified fibrinogen displays convulxin insensitivity
Because thrombin can act on numerous proteins in plasma, washed platelets were placed in a buffer containing purified fibrinogen to explore the role of soluble fibrin (C) Thrombin-induced convulxin insensitivity does not require GPVI shedding. Activation of platelets by thrombin resulted in attenuation of subsequent convulxin-induced calcium mobilization even in the presence of GM6001, which blocks GPVI shedding. When GPRP was present to block fibrin polymerization, thrombin treatment had no effect on convulxin sensitivity, even in the presence of GM6001, which blocks GPVI shedding. C, convulxin; T, thrombin. generation. Distinct from PRP, this buffer does not contain plasma antithrombin or FXIII. The washed platelets were incubated with human fibrinogen (500 nM) with and without GPRP for 10 min before the assay (Fig. 7A) . Exposure of the washed platelets in purified fibrinogen to a low dose of thrombin (1 nM) for 480 s caused a marked attenuation of the subsequent convulxin response (Fig. 7B) . Similar to the PRP experiments, GPRP prevented the thrombin-dependent signaling defect in response to convulxin. Soluble fibrin assemblies reached a size of 1.095 AE 0.347 lm after 10 min of thrombin-fibrinogen reaction, as detected by light scattering ( Figure S7 ).
Presence of soluble fibrin reduces platelet deposition to collagen under flow
Fluorescent fibrinogen (0.788 mg mL À1 ) was incubated in either 5 mM GPRP or HBS (control condition) for 10 min. Following incubation, 2.5 nM thrombin was added to generate either soluble fibrin monomer (GPRP present) or soluble fibrin polymer (HBS control). After 300 s, thrombin activity was inhibited with 100 lM PPACK. The resulting solutions were diluted by a factor of 10 in PPACK/apixaban-treated whole blood (treated to prevent endogenous thrombin production or thrombin activity). Platelet deposition from whole blood with 230 nM soluble fibrin monomer (GPRP condition) or 230 nM soluble fibrin polymer (HBS control condition), nominal concentrations assuming 100% fibrinopeptide release by thrombin, was then tested on collagen at a wall shear rate of 200 s À1 (Fig. 8A ).
As expected, 5 mM GPRP substantially blocked the amount of fibrin that co-deposited with the platelets (Fig. 8C-E) . This indicated that~8000 nM fibrinogen in whole blood outcompeted 230 nM fibrin monomer for platelet binding. In contrast, 230 nM soluble fibrin polymer added to whole blood co-deposited with platelets, even in the presence of normal levels of fibrinogen. When GPRP is present, there still appears to be a small amount of fibrin detected by fluorescence, which can be attributed to platelet-bound fibrinogen or soluble fibrin monomer. Consistent with a defect in collagen-induced platelet activation via GPVI, the presence of soluble fibrin polymer (HBS control condition) caused a substantial reduction of platelet deposition on collagen (Fig. 8B-E) , especially after~100 s when ADP and thromboxane release are especially important for platelet build-up [35] .
Discussion
In coagulopathic blood, low levels of thrombin in the systemic circulation may generate soluble fibrin monomers and small submicron-scale soluble protofibrils (< 10-50 monomers) that never reach the point of gelation. Several lines of evidence are presented that soluble fibrin, not thrombin cleavage of PARs, was the cause of GPVI-signaling deficiency in response to convulxin, CRP and collagen. PAR-1 and PAR-4 activating peptides that trigger calcium mobilization had no effect on convulxin response. Vorapaxar, which blocked thrombin-induced calcium signaling, had no effect on thrombin-mediated convulxin insensitivity. Agonists such as ADP and U46619, which similarly trigger signaling through Ga qcoupled receptors, were not able to alter subsequent convulxin sensitivity. Importantly, GPRP blocked the ability of thrombin to attenuate platelet sensitivity to convulxin. Also, the time of thrombin exposure and kinetics of onset were consistent with fibrin monomer generation and soluble fibrin multimerization. Thrombin treatment of washed platelets did not induce convulxin insensitivity, unless platelets were supplemented with purified fibrinogen. Both the calcium mobilization assay with fibrillar collagen (Fig. 2) and microfluidic platelet deposition from flowing whole blood on collagen-coated surfaces (Fig. 8) indicated that exposure of plasma to thrombin drives an attenuation of platelet GPVI signaling in response to collagen.
To test the findings under non-dilute PRP conditions, we used aggregometry to generate soluble fibrin under nonstatic conditions and challenge GPVI through addition of convulxin. The results were consistent with those observed in the calcium mobilization experiments: a low dose of thrombin with stirring (1200 rpm) permitted fibrin polymerization and subsequent addition of GPVI agonists shows a significant (~35%) reduction in aggregation compared with the control, a result that is completely reversed with GPRP ( Figure S8 ). Platelet aggregation in PRP and platelet deposition from whole blood in a microfluidic device were reduced by a similar amount when fibrin was allowed to polymerize, an effect reversed by GPRP. Given the multimeric nature of most GPVI activators, it was not unexpected that fibrin monomer that exists in the presence of GPRP was insufficient to block GPVI activation.
GPVI deficiency is extremely rare and not linked to a strong bleeding phenotype in healthy individuals. However, GPVI-deficient patients can display spontaneous bleeds [36] . The potential risk of genotypic GPVI deficiency in combination with trauma is unknown. Importantly, a combined deficiency in mouse platelet PAR-4 and GPVI causes a severe bleeding phenotype in the tail-bleed assay [37] . A level of only 1% conversion of fibrinogen (90 nM soluble fibrin) would be sufficient to overwhelm platelet GPVI, which exists at~1 nM in PRP, as the avidity of binding between polyvalent soluble fibrin and clustering receptors on platelets may be much stronger relative to the Kd of the monovalent affinity involving soluble forms of ligand and receptor. Because soluble fibrin can circulate without rapid clearance and GPVI signaling through fibrin is fairly weak compared with that driven by collagen, platelet hypofunction of endogenous or transfused platelets may be a cofactor in certain coagulopathies.
We were obliged to highlight recent work demonstrating platelet GPVI as a receptor for fibrin, which was also found to bind to a distinct configuration of GPVI [38] . In that study, sonicated crosslinked fibrin (but not D-dimer) caused < 10% washed platelet aggregation over 6 min, whereas 30 lg mL À1 D-dimer substantially inhibited platelet aggregation by subsequent challenge by 0.1-0.3 lg mL À1 collagen (but interestingly not higher doses of collagen). As [38] , an agent that selectively blocks the interaction of fibrin but not collagen with GPVI has potential as an antithrombotic therapy with reduced bleeding risk. Such an agent might hypothetically also protect circulating platelet function in trauma patients with circulating levels of soluble fibrin polymer and lytic assemblies of D-dimer. Our results and prior studies of fibrin activation of GPVI during thrombosis [21, 26] are not particularly discordant on close examination. To mimic systemic blood changes and subsequent local hemostatic response, we challenge GPVI with a subsequent agonist after preexposure to soluble fibrin. In studies of thrombus generation at a wound site, there is no additional GPVI ligand added to the assay other than the original fibrin generated in the clot [21, 26] . Also, there is no reason to expect submicron soluble fibrin multimers bound to a platelet in suspension to induce the same signaling as a spread platelet experiencing large expanses of solid-phase fibrin gel. Because platelets (and many other cell types) can sense the rigidity of their adhesive-mechanical environment [39] , we suggest that platelet signaling on solid fibrin presented on glass/plastic or in a clot may be different from platelets in suspension interacting with soluble fibrin. We also observed that soluble fibrin multimers induced a weak signal in our assay that was blocked by GPRP (Fig. 5C) .
We found GPVI attenuation occurred acutely at~200 s with 2 nM thrombin treatment (Fig. 3B, C) and was not blocked by a metalloprotease inhibitor (Fig. 6C ). This timescale of GPVI attenuation and the potency of GPRP to block convulxin insensitivity was fully consistent with the known dynamics of fibrin polymerization, which typically requires < 5-10 min. Several prior studies have demonstrated minimal soluble GPVI release over 60 min exposure of PRP to tissue factor (200 nM peak thrombin) or to thrombin (1 U mL À1 ), both of which generate fibrin in PRP [40, 41] . Thrombin alone does not release soluble GPVI from washed platelets [42] , fully consistent with an absence of convulxin insensitivity following strong thrombin stimulation of washed platelets ( Figure S4 ). Even strong agonists like collagen, convulxin or factor Xa typically require 60 min for full release of soluble GPVI. The exposure of washed platelets to one of the most potent inducers of shedding, factor Xa, did not phenocopy the kinetics or severity of GPVI-signaling defects ( Figure S9 ) that we observed with soluble fibrin generation. Thus, the observed rapid and acute attenuation of convulxin sensitivity is highly unlikely to be caused by fibrin-induced GPVI shedding, which is also fully consistent with the lack of effect of GM6001 (Fig. 6C) . GM6001 is a known inhibitor of ADAM-mediated GPVI shedding [40] [41] [42] [43] . Platelet GPVI shedding is regulated primarily by ADAM-10 [44] , and may also be facilitated by other members of the a-disintegrin-and-metalloproteinase family (such as ADAM-17) [45] . The GM6001 result supports the conclusion that soluble fibrin polymer blocks other more potent ligands from binding GPVI, an effect not requiring GPVI shedding. Because fibrin in clots is known to bind GPVI, soluble fibrin is likely to be serving as a receptor antagonist to sterically block other ligands from binding. The observed data do not prove mechanism, but are most consistent with (i) steric hindrance of GPVI by soluble fibrin species bound to the receptor and/or (ii) soluble fibrin-triggered GPVI signaling that desensitizes the receptor. The observations were not consistent with GPVI shedding, Ga q -dependent GPVI attenuation or a IIb b 3 -mediated GPVI attenuation as mechanisms of the observed phenotype. Distinct from the role of intrathrombus generation of fibrin, low levels of non-gelling, soluble fibrin may function differently in the context of trauma to cause an acquired GPVI-signaling defect in the systemic circulation. Generation of low and transient levels of thrombin in coagulopathic blood may generate circulating soluble fibrin able to bind platelet GPVI to cause platelet insensitivity to stronger GPVI agonists such as collagen. Soluble fibrin is a long-lived species once it is generated, so platelet transfusion therapies for high-risk trauma patients may become affected by these pre-existing species in the systemic circulation. If transfused platelets display an acquired deficiency in GPVI signaling in trauma patients with elevated soluble fibrin, the extraordinary hemostatic demands essential for survival may not be fully achieved. 5T32HL007954-18 (C. C. Verni), and NIH UM1 HL120877 (TACTIC Consortium), and U01 HL131053 (S. L. Diamond).
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Additional Supporting Information may be found in the online version of this article: Fig. S1 . Dasatinib, a Src family/Syk inhibitor, blocks the GPVI-signaling pathway, confirming that convulxin or collagen activates GPVI with concomitant calcium mobilization and platelet activation dependent on Syk signaling. Fig. S2 . Pretreatment of PRP with thrombin blocks subsequent platelet activation by collagen related peptide (CRP). Fig. S3 . Vorapaxar is a specific PAR-1 inhibitor. Fig. S4 . Thrombin activation of washed platelets does not exhibit attenuation of GPVI activation as is observed in PRP. Fig. S5 . Inhibition of fibrin polymerization with GPRP completely eliminates down-regulation of convulxininduced platelet activation. Fig. S6 . Inhibition of glycoprotein IIb/IIIa-mediated platelet aggregation via GR144053 does not prevent GPVI down-regulation after thrombin treatment of PRP. Fig. S7 . Characterization of soluble fibrin via dynamic light scattering. Fig. S8 . Low-dose thrombin treatment (2 nM) of PRP results in~35% decrease in platelet aggregation in response to convulxin (orange curve). Fig. S9 . Factor Xa is an effective mediator of GPVI shedding, though the process is relatively slow and requires > 60 min to exhibit~80% of the original GPVI signal.
